Blockade of OX40-OX40L Interactions Attenuates Allograft Rejection Mediated by CD4 T Cells That Recognize Alloantigen through the Direct but Not Indirect Pathway of Allorecognition

Blockade of OX40-OX40L Interactions Attenuates Allograft Rejection Mediated by CD4 T Cells That Recognize Alloantigen through the Direct but Not Indirect Pathway of Allorecognition

Bibliographische Detailangaben
Hauptverfasser:	Kinnear, G, Wood, K, Fallah-Arani, F, Jones, N
Format:	Conference item
Veröffentlicht:	2012

Ähnliche Einträge

A diametric role for OX40 in the response of effector/memory CD4+ T cells and regulatory T cells to alloantigen.
von: Kinnear, G, et al.
Veröffentlicht: (2013)

Role of OX40-OX40L interactions in the immune response to solid organ allografts
von: Kinnear, G
Veröffentlicht: (2013)

Anti-OX40 prevents effector T-cell accumulation and CD8+ T-cell mediated skin allograft rejection.
von: Kinnear, G, et al.
Veröffentlicht: (2010)

An OX-Tra’Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis
von: Kaviyon Sadrolashrafi, et al.
Veröffentlicht: (2024-03-01)

Uptake of HLA Alloantigens via CD89 and CD206 Does Not Enhance Antigen Presentation by Indirect Allorecognition
von: Eytan Breman, et al.
Veröffentlicht: (2016-01-01)

Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes
von: Ayaka Sato, et al.
Veröffentlicht: (2025-01-01)

Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia
von: Dawei Cui, et al.
Veröffentlicht: (2019-01-01)

OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis.
von: Gwyer Findlay, E, et al.
Veröffentlicht: (2014)

Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis
von: Xiaoling Zhou, et al.
Veröffentlicht: (2022-01-01)

OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis—Focus on Rocatinlimab and Amlitelimab
von: Ana Maria Lé, et al.
Veröffentlicht: (2022-12-01)

OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand.
von: al-Shamkhani, A, et al.
Veröffentlicht: (1996)

Roquin recognizes a non-canonical hexaloop structure in the 3′-UTR of Ox40
von: Robert Janowski, et al.
Veröffentlicht: (2016-03-01)

Research progress on OX40/OX40L axis mediated T cell immunity in the course of oral lichen planus
von: LIU Yang, et al.
Veröffentlicht: (2022-07-01)

699 A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models
von: Bo Zhang, et al.
Veröffentlicht: (2020-11-01)

Mast Cell-Derived Exosomes Promote Th2 Cell Differentiation via OX40L-OX40 Ligation
von: Fei Li, et al.
Veröffentlicht: (2016-01-01)

Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma
von: Xianlong Chen, et al.
Veröffentlicht: (2022-07-01)

Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment
von: Peixin Chen, et al.
Veröffentlicht: (2021-11-01)

Breaking Immunological Tolerance through OX40 (CD134)
von: Pratima Bansal-Pakala, et al.
Veröffentlicht: (2001-01-01)

OX40L/OX40 Signal Promotes IL-9 Production by Mucosal MAIT Cells During Helicobacter pylori Infection
von: Siqi Ming, et al.
Veröffentlicht: (2021-03-01)

OX40-OX40L interaction promotes proliferation and activation of lymphocytes via NFATc1 in ApoE-deficient mice.
von: Jinchuan Yan, et al.
Veröffentlicht: (2013-01-01)

Development of OX40 agonists for canine cancer immunotherapy
von: Damien Ruiz, et al.
Veröffentlicht: (2022-10-01)

CD40-CD40 ligand-independent activation of CD8+ T cells can trigger allograft rejection.
von: Jones, N, et al.
Veröffentlicht: (2000)

CD40-CD40L independent activation of CD8+T cells can trigger allograft rejection.
von: Jones, N, et al.
Veröffentlicht: (2000)

A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab
von: Asaad Abdelhalim, et al.
Veröffentlicht: (2024-11-01)

Relationship between bladder cancer and polymorphisms of OX40 (rs17568) and OX40L (rs1234313) genes in a Turkish population
von: Osman Bilen, et al.
Veröffentlicht: (2023-03-01)

Enhancement of the Soluble Form of OX40 and OX40L Costimulatory Molecules but Reduction of the Membrane Form in Type 1 Diabetes (T1D)
von: Jingnan An, et al.
Veröffentlicht: (2019-01-01)

Lymphatic Reconstruction in Kidney Allograft Aggravates Chronic Rejection by Promoting Alloantigen Presentation
von: Jinwen Lin, et al.
Veröffentlicht: (2021-12-01)

Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
von: William L Redmond, et al.
Veröffentlicht: (2012-01-01)

Ox-LDL increases OX40L in endothelial cells through a LOX-1-dependent mechanism
von: Q. Dong, et al.
Veröffentlicht: (2013-09-01)

OX40 is required for regulatory T cell-mediated control of colitis.
von: Griseri, T, et al.
Veröffentlicht: (2010)

OX40 facilitates control of a persistent virus infection.
von: Tobias Boettler, et al.
Veröffentlicht: (2012-09-01)

OX40 agonists and combination immunotherapy: putting the pedal to the metal
von: Stefanie N Linch, et al.
Veröffentlicht: (2015-02-01)

Tissue specific deletion of inhibitor of kappa B kinase 2 with OX40-Cre reveals the unanticipated expression from the OX40 locus in skin epidermis.
von: Georgina H Cornish, et al.
Veröffentlicht: (2012-01-01)

Corrigendum: Lymphatic reconstruction in kidney allograft aggravates chronic rejection by promoting alloantigen presentation
von: Jinwen Lin, et al.
Veröffentlicht: (2022-11-01)

OX40 stimulation enhances protective immune responses induced after vaccination with attenuated malaria parasites
von: Othman, A, et al.
Veröffentlicht: (2018)

OX40 Stimulation Enhances Protective Immune Responses Induced After Vaccination With Attenuated Malaria Parasites
von: Ahmad Syibli Othman, et al.
Veröffentlicht: (2018-07-01)

Affinity and kinetics of the interaction between soluble trimeric OX40 ligand, a member of the tumor necrosis factor superfamily, and its receptor OX40 on activated T cells.
von: Al-Shamkhani, A, et al.
Veröffentlicht: (1997)

Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade.
von: Brook, M, et al.
Veröffentlicht: (2005)

Association of OX40L gene polymorphism with multiple sclerosis in Iranians
von: Abdolreza Sotoodeh Jahromi, et al.
Veröffentlicht: (2024-03-01)

Structural Basis of a Novel Agonistic Anti-OX40 Antibody
von: Jing Zhang, et al.
Veröffentlicht: (2022-08-01)